These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27188668)

  • 1. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
    Palmbos PL; Hussain MH
    Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP Inhibitors in Prostate Cancer.
    Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
    Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers for cancer therapy with PARP inhibitors.
    Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
    Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibitors in Prostate Cancer.
    Grewal K; Grewal K; Tabbara IA
    Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging PARP inhibitors for treating breast cancer.
    Robert M; Patsouris A; Frenel JS; Gourmelon C; Augereau P; Campone M
    Expert Opin Emerg Drugs; 2018 Sep; 23(3):211-221. PubMed ID: 30251552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    Castro E; Mateo J; Olmos D; de Bono JS
    Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitors: A new era of targeted therapy.
    Tangutoori S; Baldwin P; Sridhar S
    Maturitas; 2015 May; 81(1):5-9. PubMed ID: 25708226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
    Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
    Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
    Varnai R; Sipeky C
    Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
    Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
    Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCAness and prostate cancer: diagnostic and therapeutic considerations.
    Dhawan M; Ryan CJ
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):488-498. PubMed ID: 30131605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging DNA repair deficiency in gynecologic oncology.
    Walsh CS; Hodeib M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of PARP inhibitors in prostate cancer: from specific to broader application.
    Zhang Z; Diao L; Zhang C; Wang F; Guan X; Yao X
    Front Endocrinol (Lausanne); 2023; 14():1164067. PubMed ID: 37152924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors in advanced prostate cancer: when to use them?
    Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
    Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.